Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C  by Li, Hui et al.
Available online at www.sciencedirect.com
8) 580–591
www.elsevier.com/locate/yviroVirology 375 (200Hepatitis C virus envelope glycoprotein co-evolutionary
dynamics during chronic hepatitis C
Hui Li a, Brian J. McMahon b,c, Susan McArdle a, Dana Bruden b, Daniel G. Sullivan a,
Dave Shelton a, Heike Deubner d, David R. Gretch a,e,⁎
a Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, USA
b Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska, USA
c Liver Disease and Hepatitis Program, Alaska Native Medical Center, Anchorage, Alaska, USA
d Department of Pathology, University of Washington Medical Center, Seattle, Washington, USA
e Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
Received 22 December 2007; returned to author for revision 16 January 2008; accepted 12 February 2008
Available online 17 March 2008
Abstract
Hepatitis C virus (HCV) envelope glycoprotein co-evolution was studied in 14 genotype 1-infected and treatment-naive subjects, including 7 with
mild and 7with severe liver disease. Cassettes encoding the envelope 1 gene (E1) and hypervariable region (HVR1) of the envelope 2 genewere isolated
at 38 different time points over 81 follow-up years. There were no significant differences in age, gender, alcohol use, or viral load between the mild and
severe disease groups. Virus from subjects with severe disease had significantly slower evolution in HVR1, and significant divergent evolution of E1
quasispecies, characterized by a preponderance of synonymousmutations, compared to virus from subjectswithmild disease. Phylogenetic comparisons
indicated higher similarity between amino acid sequences of the E1 and HVR1 regions with mild disease versus severe disease (r=0.44 versus r=0.17,
respectively; P=0.01). In summary, HCVenvelope quasispecies co-evolution differs during mild versus severe disease.
© 2008 Elsevier Inc. All rights reserved.Keywords: Hepatitis C virus; Envelope glycoprotein; Viral evolution; Viral fitness; Chronic liver diseaseIntroduction
Hepatitis C virus (HCV), a positive-sense, single strand RNA
virus of the family Flaviviridae (Lindenbatch and Rice, 2001), is
a major cause of chronic liver disease throughout the world (Choo
et al., 1989; Di Bisceglie, 1998; Houghton et al., 1991). HCV
infection accounts for at least 3 million cases of chronic hepatitis
in the United States, and as many as 170 million cases worldwide
(Alter et al., 1999; Kim, 2002; WHO, 1999). About 20% of
infected individuals spontaneously clear the virus in the acute
phase, while approximately 80% of cases result in persistent
viremia that frequently develops into severe liver diseases after
decades, including liver cirrhosis and hepatocellular carcinoma
(Fattovich et al., 1997; Hu and Tong, 1999; Khan et al., 2000;⁎ Corresponding author. 325 Ninth Avenue, Box 359690, Seattle, WA 98104,
USA. Fax: +1 206 341 5203.
E-mail address: gretch@u.washington.edu (D.R. Gretch).
0042-6822/$ - see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2008.02.012Serfaty et al., 1998; Villano et al., 1999). LikemanyRNAviruses,
HCVexhibits significant genetic heterogeneity as a result of high
replication rates and error-prone, non-proofreading RNA poly-
merases (Bukh et al., 1995; Martell et al., 1992). Phylogenetic
analysis has identified six genotypes or clades of HCV, each with
multiple discrete subtypes (Robertson et al., 1998; Simmonds,
1995). In addition, HCV within a persistently infected individual
is composed of a dynamic population of close-related, yet hetero-
geneous sequences, known as quasispecies (Bukh et al., 1995;
Martell et al., 1992). The highest levels ofHCVgenetic variability
are displayed in the two envelope glycoproteins E1 and E2, with
maximum heterogeneity within the N-terminus of E2, commonly
referred to as hypervariable region 1 (HVR1).
Although the error-prone nature of viral RNA polymerases
provides the biochemical bases for rapid viral evolution (Holland
et al., 1982), the quasispecies diversity is not generated by nu-
cleotide substitutions during replication alone (Kurosaki et al.,
1993; Lu et al., 2001). Immune pressure, involving neutralizing
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also thought to be the primary force driving HCV quasispecies
evolution in vivo (Kato et al., 1993; Kurosaki et al., 1993;
Neumann et al., 1998; Weiner et al., 1992; Zibert et al., 1995).
HVR1, a 27 amino acid sequence located in the N-terminus of E2
protein, forms a major virus surface antigen and is the dominant
epitope for strain-specific neutralizing-antibody responses (Farci
et al., 1994, 1996; Rosa et al., 1996; Shimizu et al., 1994, 1996;
Zibert et al., 1997, 1995). The extensive sequence variability
displayed in HVR1 correlates with the emergence of antibody
escape mutants, and appears to play an essential role in main-
tenance of viral persistence during chronic infection (Erickson
et al., 2001; Kurosaki et al., 1993;McAllister et al., 1998; Shimizu
et al., 1994; van Doorn et al., 1995; Weiner et al., 1991, 1992).
Studies in immunosuppressed individuals have consistently re-
ported reduced or absent variability in HVR1, presumably due to
attenuation of humoral immune responses (Booth et al., 1998;
Gaud et al., 2003; Gretch et al., 1996; Kumar et al., 1994; Qin
et al., 2005; Sullivan et al., 1998). In spite of the high variability of
HVR1, a strong negative selection is also observed against certain
amino acid substitutions over the whole viral genome, which
might indicate that conservative amino acids play important bio-
logical roles in the virus life-cycle (McAllister et al., 1998; Penin
et al., 2001; Sobolev et al., 2000).
The genetic heterogeneity of HCV quasispecies has been
shown to correlate with the evolution of chronic infection, out-
come of antiviral therapy, and progression of liver disease
(Arenas et al., 2004; Farci et al., 2000, 2002; Pelletier et al.,
2000; Ray et al., 1999; Sanchez-Fueyo et al., 2001). Dynamic
evolution of HVR1 correlates with outcome of acute infection:
subjects harboring stable viral populations frequently clear acute
infection, while those with diversifying quasispecies progress to
chronic infection (Farci et al., 2000; Ray et al., 1999). Higher
quasispecies diversity in baseline specimens has been linked to a
poor response to antiviral therapy (Farci et al., 2002; Morishima
et al., 2006; Polyak et al., 1998). Finally, longitudinal studies of
HCV infections after orthotopic liver transplantation (OLT) in-
dicated that the complexity and diversity of HCV quasispecies
are predictive of the histological severity of hepatitis C disease
recurrence in liver allografts (Arenas et al., 2004; Gretch et al.,
1996; Pelletier et al., 2000; Sanchez-Fueyo et al., 2001; Sulli-
van et al., 1998). Low diversity quasispecies are associated with
worse disease in the post-transplant setting.
Previous studies of HCV quasispecies during natural infection
have been conflicting. A missing element in all previous reports
was a long-term longitudinal cohort of treatment-naive subjects
with well-characterized patterns of disease progression. In a recent
study, we recruited fifty-two treatment-naive subjects with chronic
HCV genotype 1 infection over multiple decades and known
disease status based on liver biopsy results (Sullivan et al., 2007).
The long-term dynamics of HCV infection and their associations
with hepatitis C disease were analyzed. Subjects that developed
mild disease had higher serum RNA titers after 2 decades of
infection, greater fluctuations in serum HCV titers over time, and
higher rates of HVR1 diversification over time compared to
subjects that developed severe disease. In the present study, we
analyzed the evolutionary dynamics of the E1 glycoprotein genein addition to HVR1 of the E2 glycoprotein gene in 7 subjects
with severe disease and 7 non-diseased subjects randomly
selected from the above cohort. Genetic parameters and their
behaviors over time were carefully compared between viral
genomes isolated from the two subject groups, and molecular
evolutionary patterns associated with disease progression were
identified for the E1 and HVR1 regions during chronic infection.
Results
Patient characteristics
The fourteen subjects included in this study all underwent at
least one liver biopsy on, or in the case of some subjects with
mild disease, after the time point of the last serum collection.
Seven subjects were defined as non-progressors with mild
disease (fibrosis score of 0 or 1), and seven were defined as
progressors with severe disease (bridging fibrosis or cirrhosis,
fibrosis score of 3 or 4). Five of the subjects had more than 1
liver biopsy result available. Subjects in the two disease groups
were comparable in most clinical and virological features, in-
cluding gender (3 females in the mild group vs. 2 females in the
severe group, P=1.00), genotype (four genotype 1a and three
genotype 1b in the mild group vs. five genotype 1a and two
genotype 1b in the severe group, P=1.00), mean viral load
(5.2 log IU/ml vs. 5.5 log IU/ml for the mild and severe groups,
respectively, P=0.22), estimated duration of HCV infection
(mean 18 years in the mild group vs. 21 years in the severe
group, P=0.56), average number of specimens (2.6 in the mild
group vs. 2.8 in the severe group, P=0.74), and years of follow-
up (mean 7.4 years in the mild group vs. 7.3 years in the severe
group, P=0.93). However, subjects in the two groups differed
with respect to age (48 years in the mild group vs. 36 years
in the severe group, P=0.06), and the severe disease group
had a lower mean age at infection than the mild disease group
(30 years in the mild group vs. 15 years in the severe group,
Pb0.01). Since older age normally associates with more severe
hepatitis C (Poynard et al., 1997), the fact that our mild disease
subjects were older and were infected at an older age only
strengthens confidence that disease classifications were accurate.
Intra-specimen genetic parameters
To characterize genetic parameters of the E1 gene and HVR1 of
the E2 gene of HCV, extensive sequence analysis of quasispecies
present in the serial serum samples was performed. 362 nucleotide
sequences encompassing the region from nucleotide 817 at the end
of the HCV core gene to nucleotide 1626 in E2were obtained, with
169 sequences from 18 serial specimens of the individuals with
mild disease and 193 sequences from 20 serial specimens of the
individuals with severe disease. Intra-specimen genetic hetero-
geneity parameters of the E1 and HVR1 quasispecies are sum-
marized inTable 1. In theE1 region, non-synonymous substitutions
(dN) were significantly less frequent than synonymous substitu-
tions (dS) in both the mild and severe disease groups, with mean
dN/dS ratios of 0.2627 and 0.1896, respectively. In contrast, non-
synonymous substitutions predominated in HVR1 in both disease
Table 1
Comparison of intra-specimen genetic parameters between the subjects with mild disease and the subjects with severe disease (data shown with standard deviation)
No. of
subjects
No. of
specimen
E1 HVR1
dS dN dN/dS Nucleotide
distance
Amino acid
distance
dS dN dN/dS Nucleotide
distance
Amino acid
distance
Mild 7 18 0.0232
(0.0040)
0.0044
(0.0007)
0.2627
(0.0331)
0.0092
(0.0013)
0.0091
(0.0010)
0.0376
(0.0113)
0.0586
(0.0211)
1.4240
(0.3944)
0.0576
(0.0179)
0.1393
(0.0462)
Severe 7 20 0.0348
(0.0048)
0.0050
(0.0011)
0.1896
(0.0265)
0.0124
(0.0018)
0.0115
(0.0025)
0.0459
(0.0139)
0.0527
(0.0166)
1.2283
(0.2864)
0.0592
(0.0154)
0.1324
(0.0349)
P-value 0.10 0.92 0.08 0.18 0.86 0.54 0.72 1.00 0.59 0.46
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subjects with mild disease and 7 of 16 time points in the subjects
with severe disease. Themean dN/dS values of E1 andHVR1were
not significantly different when comparing sequences from the two
disease groups, although a trend towards differences between
groups was evident in the E1 gene (mean dN/dS of 0.2627 versus
0.1896 for the mild versus severe disease group; P=0.08). Genetic
distance was also compared between the two disease groups with
respect to both nucleotide and deduced amino acid sequences.
There was no significant difference in genetic distance in either E1
or HVR1 between the subjects with mild disease and those with
severe disease.
Next, intra-specimen dS, dN, dN/dS ratio, genetic distance
and Shannon entropy were analyzed as a function of duration of
infection for the time periods of 5–10 years, 11–19 years and
20–25 years after infection (Figs. 1 and 2). Wide fluctuations in
HCV genetic parameters were observed over time in both
groups of subjects. However, as shown in Figs. 1A and B, viral
populations in the individuals with severe disease accumulated
significantly more synonymous and non-synonymous substitu-
tions in the E1 region during the three decades of chronic HCV
infection compared to the individuals with mild disease (P=0.03
for dS, and P=0.02 for dN). For HVR1, there was no consistent
trend in accumulation of synonymous and non-synonymous
substitutions in either disease group (Figs. 2D and E), althoughFig. 1. Variation of intra-specimen dS, dN and dN/dS ratio of the E1 and HVR region
Panel A, synonymous substitution rate of the E1 region in the mild and severe disease
and severe disease groups. Panel C, non-synonymous to synonymous (dN/dS) ratio
substitution rate of the HVR1 region in the mild and severe disease groups. Panel E
disease groups. Panel F, non-synonymous to synonymous (dN/dS) ratio of the HVRthe mean dN/dS value of HVR1 exhibited a decreasing trend
over time in the subjects with severe disease (Fig. 2F). A detailed
illustration of the intra-specimen genetic distance and Shannon
entropy of the E1 region is shown in Fig. 2. Comparison of the
nucleotide and amino acid distances showed no significant
changes over time in subjects with mild disease, but revealed an
increase of genetic distances in those with severe disease, which
was statistically significant between the first and third decades
(P=0.01 for both nucleotide and amino acid distances, respec-
tively) (Figs. 2A and C). At the time period 20–25 years after
infection, the mean E1 genetic distances in the subjects with
severe disease were higher than those in subjects with mild
disease, for both nucleotide and amino acid populations (P=0.02
and 0.06 for nucleotide and amino acid distances, respectively).
For HVR1, the genetic distances were relatively stable over de-
cades in both disease groups (data not shown). Shannon entropy
was also plotted to determine whether the viral population vari-
ability differed according to disease progression (Figs. 2B and D).
In the mild disease group, nucleotide and amino acid entropy
exhibited only moderate variation in the E1 region during HCV
infection, whereas both indices increased in the severe group in a
pattern similar to that observed for the E1 genetic distances. The
differences between the first and third decades were statistically
significant for the nucleotide as well as the amino acid population
(P=0.01 and P=0.02 for nucleotide and amino acid distances,s according to years of disease progression in the mild and severe disease groups.
groups. Panel B, non-synonymous substitution rate of the E1 region in the mild
of the E1 region in the mild and severe disease groups. Panel D, synonymous
, non-synonymous substitution rate of the HVR1 region in the mild and severe
1 region in the mild and severe disease groups.
Fig. 2. Variation of intra-specimen genetic distance and Shannon entropy of the
E1 region according to years of disease progression in the mild and severe
disease groups. Panel A, intra-specimen nucleotide distances of the E1 region in
the mild and severe disease groups. Panel B, intra-specimen nucleotide entropy
of the E1 region in the mild and severe disease groups. Panel C, intra-specimen
amino acid distances of the E1 region in the mild and severe disease groups.
Panel D, intra-specimen amino acid entropy of the E1 region in the mild and
severe disease groups.
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nificant variation in HVR1 over time in either disease group (data
not shown). Taken together, the data indicate that higher sy-
nonymous and non-synonymous substitution rates in E1, along
with a greater increase of quasispecies diversity and complexity in
E1, are closely associatedwith a higher likelihood of progression to
severe liver disease during long-term chronic HCV infection. The
relationship between E1 evolution and hepatitis C disease severity
is completely opposite from the relationship between HVR1
evolution and hepatitis C disease severity we recently described
(higher HVR1 genetic diversification was associated with mild
disease progression) (Sullivan et al., 2007).
Inter-specimen genetic parameters
Although intra-specimen genetic parameters serve as a good
indication of diversity and complexity of viral quasispecies at
any one point in time, they only provide limited insight of
accumulation of nucleotide substitutions and changes of viral
population over time. To further investigate the latter aspect of
HCV quasispecies biology, measurements of nucleotide substi-
tutions and genetic distances were compared between envelopeTable 2
Comparison of inter-specimen genetic parameters between the subjects with mild di
No. of
subjects
No. of pairwise
specimen
E1
dS dN dN/dS Nucleotid
distance
Mild 7 20 0.0581
(0.0072)
0.0110
(0.0014)
0.2213
(0.0190)
0.0222
(0.0027)
Severe 7 27 0.0606
(0.0041)
0.0071
(0.0010)
0.1332
(0.0186)
0.0198
(0.0014)
P-value 0.60 0.01 b0.01 0.50genes present in any paired specimens obtained from the same
individual at different time points. Table 2 compares inter-spe-
cimen genetic data from HCV-infected mild (20 specimen pairs)
and severe (27 specimen pairs) disease groups. Similar to the
intra-specimen analysis, synonymous substitutions predomina-
ted in the E1 region when data from both disease groups were
combined (dN/dSb1). Although the two disease groups exhi-
bited similar rates of synonymous nucleotide substitutions in the
E1 region (P=0.60), the rates of non-synonymous substitutions
were significantly higher in E1 genes from the mild disease
group (P=0.01), resulting in higher dN/dS ratios in the indivi-
duals with mild disease (0.2213 in the mild disease group versus
0.1332 in the severe disease group; Pb0.01). In HVR1, the
mild disease group exhibited significantly higher values of
both synonymous substitutions (0.1034 in the mild group versus
0.0704 in the severe group, P=0.02) and non-synonymous
substitutions (0.1912 in the mild group versus 0.1312 in the
severe group, P=0.03), while the overall dN/dS ratios remained
similar for both disease groups (2.570 in the mild group versus
2.407 in the severe group, P=0.26). Genetic distances between
the paired specimens were also compared between the two
disease groups. HVR1 quasispecies present in the paired sam-
ples showed higher changes in diversity and complexity over
time in the individuals with mild disease than in those with
severe disease with respect to both nucleotide distances (0.1826
in the mild group versus 0.1360 in the severe group, P=0.03)
and amino acid distances (0.4405 in the mild group versus
0.3404 in the severe group, P=0.07). E1 quasispecies in the
mild disease group also exhibited higher amino acid distance
compared to the quasispecies in the severe group (0.0212 in the
mild group versus 0.0155 in the severe group, P=0.04).
Next, the inter-specimen genetic parameters were analyzed
relative to the more recent time point of the paired samples for the
time periods of 5–10 years, 11–19 years and 20–25 years after
infection, respectively (Figs. 3 and 4). No significant differences
were observed according to decade of infection for HVR1 bet-
ween the two disease groups (data not shown). For the E1 region,
while the synonymous substitution rate remained relatively stable
in the mild group, there was a significant increase in the dS rate
in the individuals with severe disease between the first and the
third decades (P=0.04) (Fig. 3A). At the same time, however,
little fluctuation was observed for the non-synonymous substitu-
tion rate or the dN/dS ratio in those subjects (Figs. 3B and C). E1
quasispecies present in the paired samples from subjects with
severe disease showed a progressive increase in nucleotidesease and the subjects with severe disease (data shown with standard deviation)
HVR1
e Amino acid
distance
dS dN dN/dS Nucleotide
distance
Amino acid
distance
0.0212
(0.0026)
0.1034
(0.0137)
0.1912
(0.0232)
2.570
(0.4680)
0.1826
(0.0179)
0.4405
(0.0454)
0.0155
(0.0021)
0.0704
(0.0083)
0.1312
(0.0143)
2.407
(0.1514)
0.1360
(0.0112)
0.3404
(0.0280)
0.04 0.02 0.03 0.26 0.03 0.07
Fig. 3. Variation of inter-specimen dS, dN and dN/dS ratio of the E1 region
according to years of disease progression in the mild and severe disease groups.
Panel A, synonymous substitution rate of the E1 region in the mild and severe
disease groups. Panel B, non-synonymous substitution rate of the E1 region in
the mild and severe disease groups. Panel C, non-synonymous to synonymous
(dN/dS) ratio of the E1 region in the mild and severe disease groups.
Fig. 4. Variation of inter-specimen genetic distance of the E1 region according to
years of disease progression in themild and severe disease groups. Panel A, inter-
specimen nucleotide distances of the E1 region in the mild and severe disease
groups. Panel B, inter-specimen amino acid distances of the E1 region in the mild
and severe disease groups.
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infection (P=0.02), whereas E1 quasispecies from subjects with
mild disease did not show this evolutionary pattern (Fig. 4A).
Phylogenetic analysis and the co-evolution coefficients between
E1 and HVR1 of E2
Phylogenetic reconstruction was performed on nucleotide
sequence alignments to assess the specific evolutionary patterns
of E1 and HVR1 according to disease progression. Phylogenetic
trees for representative subjects from both disease groups are
shown in Fig. 5. As seen in the left part of the figure, the E1
quasispecies sequences diverged away from the initial viral po-
pulation in both disease groups, with similar patterns of evolu-
tionary drift. Interestingly, the sequence cluster of the third time
point (1996) from the subject with severe disease drifted toward
the initial time point (1989) instead of diverging away as a discrete
lineage, suggesting that these variants were selectively advanta-
geous between the second and third time points and were fixed as
the major viral population. Divergent evolution was also evident
in HVR1 from subjects in the mild disease group, with three
distinct evolutionary clusters corresponding to the three time
points, which exactly corresponded to the clusters in the E1
phylogenetic tree (Fig. 5A, the left panel). However, HVR1
sequences from the representative subject with severe disease
were closely related to each other, and showed little evidence ofdivergent evolution when variants at different time points were
compared (Fig. 5B, right panel).
To evaluate E1 and HVR1 co-evolution and its association
with the disease progression, we compared interrelatedness
between the E1 and HVR1 phylogenetic trees from each study
subject. Similarity between the phylogenetic trees was evaluated
for statistical association of correlation coefficients, and inter-
preted as an indication of coordinated evolution under a similar
evolutionary pressure (Pazos et al., 2005; Pazos and Valencia,
2001). Genetic distance was calculated for each individual E1 or
HVR1 sequence by comparing the sequence to all the other E1 or
HVR1 sequences obtained from the same subject. Then, a linear
correlation coefficient was evaluated between the data set of E1
and HVR1 genetic distances for each subject. All of the corre-
lation coefficients are plotted according to disease groups in
Fig. 6. The correlation of amino acid distances between E1 and
HVR1 was significantly higher among the subjects with mild
disease compared to those with severe disease (r=0.44 versus
r=0.17, P=0.01). These data indicate that the E1 glycoprotein
and HVR1 of the E2 glycoprotein evolve at a higher coordinate
level in the subjects with mild disease compared to the subjects
with severe disease.
Amino acid comparisons and signature sequence analysis of E1
To determine whether specific amino acid usage patterns
were associated with disease outcomes, the deduced consensus
amino acid sequences of E1 from each subject were assessed and
compared between the mild and severe disease groups (Fig. 7).
HVR1 amino acid comparisons between disease groups were
previously reported (Sullivan et al., 2007). The 14 consensus E1
sequences exhibited complete conservation at 126 of the 192
(66%) amino acid positions, suggesting that the E1 region is
under a high degree of purifying selection. There were 5 putative
Fig. 5. Phylogenetic trees constructed according to the amino acid sequences of the E1 andHVR regions obtained from representative individuals within themild and severe
disease groups. The trees were constructed with the neighbor-joining method, and Poisson-correction distances were shown with each branch. Panel A, phylogenetic trees
based on the E1 (on the left) and HVR (on the right) amino acid sequences from a representative individual withmild disease. Sequences at various time points are indicated
by various symbols (□, 1987; ■, 1988; ○, 1996). Panel B, phylogenetic trees based on the E1 (on the left) and HVR (on the right) amino acid sequences from a
representative individual with severe disease. Sequences at various time points are indicated by various symbols (□, 1989; ■, 1994; ○, 1996; ●, 1997).
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Dubuisson, 2003; Meunier et al., 1999) and 8 cysteine residues
present throughout the E1 region, and all of them were highly
conserved among the 14 sequences except one potential glyco-
sylation site which presented an N to S mutation in 58% of
sequences from a subject with severe disease (S030).VESPA program was used to search for signature motifs
between the mild and severe disease groups. Three amino acid
positions were identified at which the majority amino acid
differed according to disease groups: position 219 with 2T 2A
2M 1V in the mild group and 4A 2M 1T in the severe group,
position 235 with 3S 2A 1I 1T in the mild group and 2V 2T 1A
Fig. 6. Linear correlation coefficients between genetic distances of the E1 and
HVR regions in the mild and severe disease groups. Panel A, linear correlation
coefficients between nucleotide distances of the E1 and HVR regions in the mild
and severe disease groups. Panel B, linear correlation coefficients between amino
acid distances of the E1 and HVR regions in the mild and severe disease groups.
586 H. Li et al. / Virology 375 (2008) 580–5911I 1S in the severe group, and position 359 with 4L 3I in the
mild group and 4I 2L 1V in the severe group. However, none of
the majority amino acids at these positions was unique to either
group of subjects. The pI values were evaluated for the con-
sensus E1 sequences from each individual subject; sequences
from the subjects with severe disease were more positively
charged than those from subjects with mild disease (pI=8.16
versus pI=7.32, P=0.14).
Discussion
In the present study, the evolution of the HCV envelope
glycoproteins was analyzed in patients selected from a cohort
with long-term chronic HCV infection followed prospectively
to determine viral factors associated with the progression to
cirrhosis. Subjects with HCV genotype 1 infection and who had
not received any antiviral therapy were recruited and divided
into two groups, one with severe disease and one with mildFig. 7. Alignment of the consensus amino acid sequences of the E1 region from eac
glycosylation site (NXT or NXS); #, cysteine residue.disease, based on histological findings on liver biopsy. 362
nucleotide sequences encompassing the E1 and HVR1 regions
were generated from sequential serum specimens, and subjected
to various phylogenetic analyses. The evolutionary trend of the
E1 and HVR1 regions differed markedly according to disease
status. As previously reported in the HCV-infected liver trans-
plant model (Arenas et al., 2004; Gretch et al., 1996; Lyra et al.,
2002; Sullivan et al., 1998), the HCV and HIV coinfection
model (Qin et al., 2005), and during natural infection (Curran
et al., 2002; Sullivan et al., 2007), reduced genetic diversifica-
tion of HVR1 over time correlated with severe disease. In
contrast, the present results demonstrate that during natural
infection, severe disease was associated with increased diver-
sification of the E1 glycoprotein gene over time, with progressive
accumulation of both synonymous and non-synonymous muta-
tions. Comparison of E1 and HVR1 phylogenetic trees demon-
strated that the two regions were less evolutionarily correlated in
the individuals with severe disease.
A major limitation of the study is the relatively small sample
size, making it premature to draw conclusions on the association
between HCV glycoprotein evolution and disease progression in
hepatitis C. For example, dN/dS ratios in HVR1 appeared to
decline over time during severe disease, yet increase over time
during mild disease (Fig. 1, panel F). Such data might imply that
immune pressure on HVR1 decreased over time during disease
progression. However, the data did not reach statistical signi-
ficance, possibly because of the limited sample size. Therefore,
larger studies are needed to confirm the present findings. A major
strength of this study is that the two disease groups were verywell
defined and matched (e.g., all therapy naive, all infected with
genotype 1, concomitant infections rigorously excluded, equiva-
lent alcohol use, all were Alaska Natives and American Indians),
disease endpoints were well defined by liver biopsy, sampling
was extensive, and quality genetic data were obtained. Verifica-
tion of these findings is warranted by the potential clinical
significance of HCV quasispecies biology, including the associa-
tion between low HVR1 diversity and more severe disease
outcome (Sullivan et al., 2007), and the association between high
HVR1 diversity and poor response to interferon-based therapiesh individual subject with mild (M) and severe (S) disease. ⁎, putative N-linked
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Nucleotide substitutions of HVR1
HVR1 of E2, with the highest nucleotide substitution rate of
the HCV genome, has been used as the most popular target in
molecular studies of HCV quasispecies heterogeneity and
phylogenies (Alfonso et al., 2004; Allain et al., 2000; Curran
et al., 2002). Host immune pressure is considered to be the
primary force driving quasispecies evolution in this region (Booth
et al., 1998; Farci et al., 1994, 1996; Ray et al., 1999; Shimizu
et al., 1994, 1996). With non-synonymous substitutions pre-
dominant, the evolution of HVR1 occurs under immune pressure,
either by fixation of spontaneous mutations at specific sites, or by
shifts of major variants in a quasispecies (Lu et al., 2001).
Variations are unequally distributed within HVR1, with the pre-
sence of both highly variable and highly conserved positions. It
has been suggested that the positively selected sites are most
likely to be surface-exposed, and therefore prime targets for host
antibody responses (Wack et al., 2001; Yagnik et al., 2000). At the
same time, a negative pressure is probably exerted against con-
served positions essential for confirmation conservation and/or
host cell attachment (Penin et al., 2001). Previous investigators
have proposed that HVR1 acts as an immunologic decoy during
HCV infection, stimulating a strong yet ineffective immune res-
ponse that results in a genetically unstable population without
producing significant growth disadvantages or effective antiviral
control (Ray et al., 1999; Sheridan et al., 2004). The present study
could not determine the extent that quasispecies homogenization
resulted from reduced immune pressure, versus accumulation of
variants that successfully escaped antibody responses, versus
formation of an equilibrium between the viral population and host
immune responses.
Nucleotide substitutions of E1
E1 is a type-I transmembrane glycoprotein with a short
C-terminal transmembrane domain of about 30 amino acids (De-
leersnyder et al., 1997; Op De Beeck et al., 2000). E1 shares
sequence similarity to the scaffold of class II membrane-fusion
protein as observed in other members of the Flaviviridae family
(Garry and Dash, 2003). By forming noncovalent heterodimers
with E2, E1 plays pivotal roles in binding to receptors during
host cell recognition and inducing fusion with the cell mem-
brane (Bartosch et al., 2003). In contrast to HVR1 of E2, the E1
glycoprotein is reported to have a high degree of sequence con-
servation, appears to be less immunogenic in vivo, and by in-
ference, is less likely to be surface-exposed (Allison et al., 2001;
Fournillier et al., 2001). Our present results confirm that the dN/
dS ratio of the E1 region is significantly lower than 1, regardless
of patient disease status, suggesting that the majority of positions
within E1 are under strong negative selection with amino acid
constraints. The data may indicate a need to conserve E1 protein
modification and/or folding processes that determine the gly-
coprotein confirmation and/or specific virus-cell receptor inter-
actions during viral recognition and attachment to the host cells.HCV glycoprotein dynamics and disease progression
Absolute nucleotide substitution rates can provide great
insight into factors involved in a change of the evolutionary
process (Seo et al., 2004). Synonymous substitution rates can be
affected by differences in viral generation time or reproductive
rate, while non-synonymous substitution rates can be altered by
either viral generation time, changes in patterns of selection, or
effective viral population size. In the present study, inter-spe-
cimen synonymous and non-synonymous substitution rates of
the HVR1 region were consistently higher in subjects with mild
disease, and viral quasispecies accumulated more genetic hete-
rogeneity between different time points compared to virus in-
fecting subjects with severe disease. In the post-transplant setting,
subjects with severe disease had significantly reduced CD4+
T cell responses against HCVantigens compared to subjects with
mild disease (Rosen et al., 1999), suggesting that deficient host
immune responses may contribute to quasispecies homogeniza-
tion in HVR1 during severe disease. Unfortunately, immunology
data are not yet available for the present cohort.
In contrast to HVR1, E1 glycoprotein genetics accelerated
during severe disease, with increasing dS and dN substitution
rates resulting in increasing genetic heterogeneity at both the
nucleotide and amino acid levels. Increases in both dS and dN
within a poorly immunogenic region (such as found in E1) sug-
gest increased replication rate. One hypothesis concerning HCV
replication dynamics is that variants with increased replication
fitness acquire survival advantages, and become the dominant
population during progression of severe disease, as has been
proposed for HIV disease (Lemey et al., 2007; Nowak and May,
2000). If true, viral emergence might be associated with reduced
host pressure (i.e., immune exhaustion), viral escape, virus-im-
mune equilibrium, or viral knockout of host control mechanisms.
Alternatively, the data may be interpreted as resulting from higher
turnover of infected cells, as proposed by Wang et al. (2007).
Previous studies have defined important interactions between
the E1 and E2 glycoproteins of HCV. Therefore, we analyzed
amino acid relationships between the two glycoproteins, according
to disease status. In subjects with mild disease, primary amino acid
sequences in E1 and HVR1 remained more closely related over
time compared to the same regions in subjects with severe disease.
The data suggest fundamental differences in co-evolutionary dy-
namics between the HCV E1 and HVR1 glycoprotein domains in
subjects with mild versus severe disease, perhaps indicating differ-
ences in the ability of virus to escape immunity, and/or differences
with respect to efficiency and specificity of cell receptor usage.
In a recent study of HCV replicative intermediate RNA using
strand-specific in situ hybridization, we reported a highly sig-
nificant association between higher indices of intrahepatic HCV
replication and more severe liver disease (Pal et al., 2006).
Diseased livers also have higher levels of HCV non-structural
antigens than non-diseased livers (Gretch et al., 1995; Hiramatsu
et al., 1992). However, HCV serum viral loads do not increase
during progression to severe disease, at least during natural
infection (Sullivan et al., 2007). The most logical explanation is
hepatic exhaustion, i.e., that more extensive liver damage results
in fewer liver cells that are capable of supportingHCVreplication.
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decreased efficiency of virogenesis as a result of intracellular
congestion and/or toxicity associated with accumulation of viral
replication products, even though viral replication is more robust.
Thus, the relationship between viral population size in circulation
and viral replication rate in liver may be different in subjects with
mild versus severe disease, a possibility that deserves further
study.
N-linked glycosylation
There are five potential N-linked glycosylation sites over the
HCV E1 glycoprotein (Goffard and Dubuisson, 2003; Meunier
et al., 1999). N-linked glycosylation sites, necessary for correct
glycoprotein confirmation and cellular entry, can be sites of
occurrence of adaptive mutations (Goffard et al., 2005; Huang
et al., 1997; Li et al., 1993; Wu et al., 1995). Changes in N-
linked glycosylation of the HIV envelope gene product, gp120,
have recently been proposed as important in neutralization
escape and viral persistence (Choisy et al., 2004; Wei et al.,
2003). In our dataset, only one glycosylation site was detected
missing, and this mutation occurred in only one subject. These
data suggest that in contrast to the glycan shield of HIV, which
can be rearranged to provide protection against neutralizing
antibodies, the major function of glycosylation of HCV E1
glycoprotein is to ensure correct glycoprotein processing, fol-
ding and cellular entry, rather than immune shielding.
In summary, the data indicate that divergent evolution of E1
and decreasing quasispecies heterogeneity in the E2 hypervariable
region strongly associated with progression to severe chronic
hepatitis C disease. Accumulation of synonymousmutations in E1
accompanied by homogenization of sequences in HVR1 im-
plicates viral outgrowth as secondary to fitness advantage. The
collective data can be interpreted to indicate that during severe
disease, variants with increased replication fitness (based on E1
genetics) successfully escaped from or equilibrated with the neu-
tralizing-antibody responses (based on HVR1 genetics). We hy-
pothesize that HCV can adapt to non-sterilizing, disease-arresting
antiviral pressures of the infected host, and that such adaptation
somehow triggers increasing severity of liver disease. To prove the
hypothesis requires systems to discriminate whether viral genetic
changes trigger disease, or whether they are simply a consequence
of other mechanisms driving disease progression.
Materials and methods
Subjects and samples
The 14 subjects included in the present study were recruited
from the cohort of Alaska Natives and American Indians (AN/
AI) cohort, and were included in previously published studies of
the long-term patterns of HCV genotype 1 infection in humans
(McMahon et al., 2004; Sullivan et al., 2007). All subjects were
negative of HIV and HBV coinfections, and all were interferon
treatment-naive. Disease status was inferred from current liver
biopsies that were systematically evaluated by a single studypathologist (HD) according to the Knodell scoring system
(Ishak et al., 1995; Knodell et al., 1981; Scheuer et al., 2002).
Seven subjects were classified with severe disease (bridging
fibrosis or cirrhosis) and seven were classified as with mild,
non-progressive disease. The date of HCV infection was esti-
mated based on risk factor data from patient interviews (the date
of first intravenous drug use or pre-1992 blood transfusion) and
was correlated with antibody seroconversion dates (Bruden
et al., 2004). A total of 38 serial serum samples was collected
from the 14 individuals over 81 follow-up years, and stored at
−80 °C for future RNA extraction.
Cloning and sequencing of E1 and HVR1
Reverse-transcription PCR (RT-PCR), cloning and sequencing
were performed as previously described by our laboratory (Wil-
son et al., 1995). RT-PCRwas performed in a 25μL volume in the
presence of anti-sense primer JBE1-1as (1639-1600, AGGCTTT-
CATTGCAGTTCAAGGCCGTGCTATTGATGTGCC) at 37 °C
for 1 h using the M-MLV reverse transcriptase kit (Invitrogen,
Carlsbad, CA). The resulting cDNA was used as template in
nested PCR to amplify a 0.84 kb fragment encompassing the E1
glycoprotein gene and HVR1 of the E2 glycoprotein gene. Ali-
quots (10 μL) of cDNA were mixed with 0.5 μM anti-sense
primer JBE1-1as and sense primer JBE1-1s (802–841, GCGT-
CCGGGTTCTGG-AAGACGGCGTGAACTATGCAACAGG),
1 mM dNTPs and 0.5 U Platinum Taq Polymerase High Fidelity
(Invitrogen, Carlsbad, CA) in a 25 μL reaction volume with
1×PCR buffer. After an initial denaturation at 95 °C for 2 min,
PCR was carried out for 35 cycles with 30 s of denaturation at
95 °C, 30 s of annealing at 55 °C, and 1min of extension at 72 °C,
followed by a final extension at 72 °C for 5 min. Then, 1 μL of the
first-round PCR product was used as template in second-round
reactions with primers JBE1-2s (817–856, AAGACGGCGT-
GAACTATGCAACAGGG-AACCTTCCTGGTTG) and JBE1-
2as (1626–1587, AGTTCAAGGCCGTGCTATTGATGTGC-
CAACTGCCGTTGGT). The second-round amplification was
carried out using identical conditions to the first-round PCR.
PCR fragments were analyzed by agarose gel electrophoresis
and extracted from the gel using Qiagen DNA purification kit
(QIAGEN Inc., Valencia, CA). The fragments were ligated into
the TA cloning vector (Invitrogen, Carlsbad, CA) and trans-
formed into Escherichia coli TOP-10 competent cells for reco-
very of plasmid clones. Eight to twelve clones representative of
each sequential time point for each subject were selected, am-
plified with primers JBE1-2s and JBE1-2as, and sequenced at
both directions using an ABI 3730XL high-throughout capillary
DNA Analyser.
Phylogenetic analysis
Nucleotide sequences were aligned using the CLUSTAL W
program (Thompson et al., 1994) included in MacVector version
9.0 (Symantec Corp., Cupentino, CA) with manual adjustment.
The rates of inter and intra-sample non-synonymous substitutions
(dN) and synonymous substitutions (dS) were estimated using the
method of Nei and Gojobori (1986) and the Synonymous/Non-
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website (http://hcv.lanl.gov/content/hcv-db/SNAP/SNAP.html)
(Korber, 2000). The resulting matrix was used to estimate mean
inter- and intra-sample dS, dN and dN/dS ratios. Protein
sequences were deduced from the nucleotide sequences using
MacVector version 9.0. Themean genetic distance was calculated
using theKimura two-parameter method and the PHYLIP version
3.5 package (Felsenstein, 1993). Shannon entropy was determine
using the Entropy program on the Los Alamos National Security
website (http://hcv.lanl.gov/content/hcv-db/ENTROPY/entropy.
html) (Korber et al., 1994). Phylogenetic trees were constructed
using the neighbor-joining method (Saitou and Nei, 1987) and
MacVector version 9.0. Signature pattern analysis was performed
using the Viral Envelope Signature Pattern Analysis (VESPA)
program (Korber and Myers, 1992).
Statistical analysis
All statistical calculationswere performed using SPSSBase 11
(SPSS Inc., Chicago, IL). To determine the associations between
patient characteristics and disease progression, independent-
sample Mann–Whitney tests were used to compare age, viral
load, age at HCV infection and length of HCV infection between
themild and severe disease groups, while Fisher's exact tests were
used for evaluating gender and genotype. Independent-sample
Mann–Whitney tests were also used to analyze differences
between the genetic parameters of mild and severe subjects as a
whole group or at various time points. The linear correlation
coefficient (r) was calculated to determine the relationship
between genetic distances of the E1 and HVR1 regions. P-values
of less than 0.05 were considered to be statistically significant.
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